Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings - BioMarin Pharmaceutical (NASDAQ:BMRN)

Core Insights - BioMarin Pharmaceutical Inc reported weaker-than-expected earnings for Q3, with earnings of $0.12 per share, missing the consensus estimate of $0.37 per share, and quarterly sales of $776.133 million, below the expected $780.629 million [1] Financial Performance - The company lowered its FY2025 adjusted EPS guidance from $4.40-$4.55 to $3.50-$3.60, while raising its sales guidance from $3.125 billion-$3.200 billion to $3.150 billion-$3.200 billion [2] - The CEO highlighted over 20% revenue growth from PALYNZIQ and VOXZOGO as key contributors to the business units [2] Stock Performance - Following the earnings announcement, BioMarin shares gained 4.3% to $54.95 [3] Analyst Ratings and Price Targets - Morgan Stanley maintained an Overweight rating but lowered the price target from $104 to $98 [5] - HC Wainwright & Co. maintained a Neutral rating and cut the price target from $60 to $55 [5] - Barclays also maintained an Overweight rating while lowering the price target from $86 to $80 [5]